Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation

Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications

“…A total of 20 case reports and one phase I/II study investigating stem-cell therapies in 108 patients (37 women, age 17–75 years, disease duration 1–38 years, follow-up 7–78 months) suffering from CIDP, MMN, and myasthenia gravis were found [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. Of these patients, 95 suffered from CIDP, 10 suffered from myasthenia gravis, and one each suffered from MMN, myasthenia gravis and concomitant amyotrophic lateral sclerosis (ALS), and myasthenia gravis and concomitant polymyositis [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ].…”

“…A total of 20 case reports and one phase I/II study investigating stem-cell therapies in 108 patients (37 women, age 17–75 years, disease duration 1–38 years, follow-up 7–78 months) suffering from CIDP, MMN, and myasthenia gravis were found [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. Of these patients, 95 suffered from CIDP, 10 suffered from myasthenia gravis, and one each suffered from MMN, myasthenia gravis and concomitant amyotrophic lateral sclerosis (ALS), and myasthenia gravis and concomitant polymyositis [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. Due to consideration of several case reports, the patients’ symptoms and disease-related disability were highly heterogeneous and scored with different clinical evaluation tools (modified Rankin scale, inflammatory neuropathy cause and treatment score, Rasch-built overall disability scale, medical research council sum score, myasthenia gravis foundation of America score, and myasthenia gravis composite score) [ 104 , 1...…”

“…Of these patients, 95 suffered from CIDP, 10 suffered from myasthenia gravis, and one each suffered from MMN, myasthenia gravis and concomitant amyotrophic lateral sclerosis (ALS), and myasthenia gravis and concomitant polymyositis [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. Due to consideration of several case reports, the patients’ symptoms and disease-related disability were highly heterogeneous and scored with different clinical evaluation tools (modified Rankin scale, inflammatory neuropathy cause and treatment score, Rasch-built overall disability scale, medical research council sum score, myasthenia gravis foundation of America score, and myasthenia gravis composite score) [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. On the one hand, there were patients, who were treated with stem-cell therapies due to the dependence of regular treatment (IVIG and plasmapheresis), but who responded well to this initial treatment and recovered completely [ 104 , 105 , ...…”

“…Due to consideration of several case reports, the patients’ symptoms and disease-related disability were highly heterogeneous and scored with different clinical evaluation tools (modified Rankin scale, inflammatory neuropathy cause and treatment score, Rasch-built overall disability scale, medical research council sum score, myasthenia gravis foundation of America score, and myasthenia gravis composite score) [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. On the one hand, there were patients, who were treated with stem-cell therapies due to the dependence of regular treatment (IVIG and plasmapheresis), but who responded well to this initial treatment and recovered completely [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. These patients were not severely disabled, and symptoms mostly did not influence daily activities [ 104 , 105 , 106 , 107 …”

“…On the one hand, there were patients, who were treated with stem-cell therapies due to the dependence of regular treatment (IVIG and plasmapheresis), but who responded well to this initial treatment and recovered completely [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. These patients were not severely disabled, and symptoms mostly did not influence daily activities [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. On the other hand, there were patients, who were treatment-refractory and/or highly disabled (including the need for intensive care and ventilation) [ 104 , 105 , 106 , 107 , 108 , 109 , 110 ,…”